| SC 13D/A | 2021-02-24 | NOVARTIS PHARMA AG | Cellular Biomedicine Group, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2021-02-22 | Dangdai International Group Co. Ltd | Cellular Biomedicine Group, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2021-02-19 | Liu Tony | Cellular Biomedicine Group, Inc. | 0 | 0.0% | EDGAR |
| SC 13D | 2020-08-14 | NOVARTIS PHARMA AG | Cellular Biomedicine Group, Inc. | 1,458,257 | 7.5% | EDGAR |
| SC 13D/A | 2020-08-12 | Liu Tony | Cellular Biomedicine Group, Inc. | 838,617 | 4.2% | EDGAR |
| SC 13D/A | 2020-08-12 | Dangdai International Group Co. Ltd | Cellular Biomedicine Group, Inc. | 2,270,000 | 11.7% | EDGAR |
| SC 13D/A | 2020-06-25 | Dangdai International Group Co. Ltd | Cellular Biomedicine Group, Inc. | 2,270,000 | 11.8% | EDGAR |
| SC 13D/A | 2020-06-24 | Liu Tony | Cellular Biomedicine Group, Inc. | 863,617 | 4.3% | EDGAR |
| SC 13D/A | 2020-06-24 | HILLHOUSE CAPITAL ADVISORS, LTD. | Cellular Biomedicine Group, Inc. | 235,214 | 1.2% | EDGAR |
| SC 13D/A | 2020-04-01 | Liu Tony | Cellular Biomedicine Group, Inc. | 863,617 | 4.3% | EDGAR |
| SC 13D/A | 2020-04-01 | TF Venture Capital Management Co., Ltd. | Cellular Biomedicine Group, Inc. | 358,974 | 1.8% | EDGAR |
| SC 13D/A | 2020-04-01 | Sailing Capital Overseas Investments Fund, LP | Cellular Biomedicine Group, Inc. | 1,712,920 | 8.9% | EDGAR |
| SC 13D/A | 2020-03-31 | Dangdai International Group Co. Ltd | Cellular Biomedicine Group, Inc. | 2,270,000 | 11.8% | EDGAR |
| SC 13D/A | 2020-03-30 | HILLHOUSE CAPITAL ADVISORS, LTD. | Cellular Biomedicine Group, Inc. | 235,214 | 1.2% | EDGAR |
| SC 13D/A | 2020-02-24 | Dangdai International Group Co. Ltd | Cellular Biomedicine Group, Inc. | 2,270,000 | 11.8% | EDGAR |
| SC 13D/A | 2020-02-21 | Liu Tony | Cellular Biomedicine Group, Inc. | 863,617 | 4.3% | EDGAR |
| SC 13D/A | 2020-02-21 | Sailing Capital Overseas Investments Fund, LP | Cellular Biomedicine Group, Inc. | 1,712,920 | 8.9% | EDGAR |
| SC 13D/A | 2020-02-21 | HILLHOUSE CAPITAL ADVISORS, LTD. | Cellular Biomedicine Group, Inc. | 235,214 | 1.2% | EDGAR |
| SC 13D/A | 2020-02-21 | TF Venture Capital Management Co., Ltd. | Cellular Biomedicine Group, Inc. | 358,974 | 1.8% | EDGAR |
| SC 13D/A | 2020-02-03 | Dangdai International Group Co. Ltd | Cellular Biomedicine Group, Inc. | 2,270,000 | 11.8% | EDGAR |